With this study, we have shown that the 3′UTRMYC1-18 drug is therapeutically effective both in vitro and in vivo in a titratable dose-dependent manner compared to the standard-of-care drugs in various MYC-driven lethal pancreatic cancers. Here, MYC is linked to pancreatic neoplasm.